-
YICAI | China's Frontier Biotech Pops After Granting GSK Rights to Two siRNA Drugs in USD1 Billion Deal
Shares of Frontier Biotechnologies surged after the Chinese drugmaker granted UK pharmaceutical giant GSK the exclusive global rights to two small nucleic acid therapies it is developing in a deal worth more than USD1 billion... -
YICAI | Global Investment Banks, Multinationals Hike Chinese Chemicals Market Exposure
Major international investment institutions, including UBS Securities and Morgan Stanley, have expressed optimism about the Chinese chemicals market, with multinational petrochemical corporations seeing China as an essential market for their development... -
China Daily | Foreign experts optimistic on A shares
Despite the latest A-share pullback, foreign financial institutions remain upbeat on China's equity markets, citing consumption-led rebalancing, shareholder return reforms and profitability improvements as key medium to long-term growth drivers... -
China Daily | China moves to strengthen disclosure on public investment funds
China's top securities regulator released on Friday draft revisions to rules on information disclosure by publicly offered investment funds, stepping up requirements on reporting investment returns to improve transparency and better protect investors... -
China Daily | CSRC steps up enforcement on private fund sector with record penalty
China's securities regulator has imposed its heaviest penalty yet on illegal behaviors involving privately offered asset management firms, underscoring its ongoing efforts to intensify crackdown on illicit activities in the private fund sector to better protect investor interests...